SPONSOR
Sichuan Baili Pharmaceutical Co., Ltd.
Total Trials
3
Recruiting
3
Phases
Phase 3, Phase 2
Sichuan Baili Pharmaceutical Co., Ltd. is a clinical research sponsor with 3 registered studies on ClinicalTrials.gov, of which 3 are actively recruiting participants. Research covers conditions including Non-squamous Non-small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma.
The trial portfolio spans Phase 3, Phase 2 studies, reflecting a pipeline that may include early-stage safety evaluations, mid-stage efficacy assessments, and large-scale confirmatory trials. All studies listed here are sourced directly from ClinicalTrials.gov and updated daily.
Frequently Asked Questions — Sichuan Baili Pharmaceutical Co., Ltd.
How many clinical trials has Sichuan Baili Pharmaceutical Co., Ltd. sponsored?
ClinicalMetric currently tracks 3 clinical trials sponsored by Sichuan Baili Pharmaceutical Co., Ltd., of which 3 are actively recruiting participants. These trials cover conditions including Non-squamous Non-small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma. Trial counts are updated daily from ClinicalTrials.gov and reflect currently registered studies.
What therapeutic areas does Sichuan Baili Pharmaceutical Co., Ltd. research focus on?
Sichuan Baili Pharmaceutical Co., Ltd. clinical trials span Non-squamous Non-small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma. The research pipeline includes Phase 3, Phase 2 trials, reflecting work from early-stage safety evaluation through large-scale efficacy studies.
How do I participate in a Sichuan Baili Pharmaceutical Co., Ltd. clinical trial?
To participate in a Sichuan Baili Pharmaceutical Co., Ltd. trial, review the active studies listed on this page, check each trial's specific eligibility criteria on ClinicalTrials.gov, and contact the trial site directly—not the sponsor's headquarters. Trial sites are academic medical centers, hospitals, or specialized research clinics. Your physician can facilitate a referral. ClinicalMetric lists all Sichuan Baili Pharmaceutical Co., Ltd. trials with current recruitment status updated daily.
Clinical Trials by Sichuan Baili Pharmaceutical Co., Ltd.
NCT07178795 Phase 3
Recruiting
A Study of BL-M07D1 vs Pembrolizumab-platinum Chemotherapy in First-line Treatment of HER2-mutant Advanced or Metastatic Non-squamous NSCLC
Non-squamous Non-small Cell Lung Cancer
NCT06437522 Phase 2
Recruiting
A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma and Other Solid Tumors
Head and Neck Squamous Cell Carcinoma
NCT07264816 Phase 2
Recruiting
A Study of BL-M07D1 in Combination With Pembrolizumab in Patients With Unresectable Locally Advanced or Metastatic HER2-Overexpressing Non-Squamous NSCLC
Non-squamous Non-small Cell Lung Cancer
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: April 2026 · Data Methodology